Issue 28 | July 2019
Greetings from the Pediatric Trials Network! I hope you are enjoying a fun and relaxing summer. A lot of exciting happenings have taken place over the past few months within the network. The PTN hosted a symposium during the recent Pediatric Academic Societies (PAS) meeting, a trial enrollment milestone was met, research findings were published, and more! See below for details.

As always, thank you for your support of PTN. Your commitment to our mission of informing formulation, dosing, efficacy, and safety of drugs and medical devices used in pediatric patients makes a huge impact.
Danny Benjamin, MD, PhD, MPH
In Review: PTN at the 2019 PAS Meeting
The annual Pediatric Academic Societies (PAS) Meeting took place April 24-26 in Baltimore, Md. As part of the leading child health research meeting, the PTN hosted an evening symposium to provide attendees an opportunity to learn more about PTN's contributions to child health and its unique perspectives as a network of more than 100 pediatric research sites across the globe.

A Review of PTN Presentations:

  • Dr. Kelly Wade of the Children’s Hospital of Philadelphia (CHOP) and Dr. Matthew Laughon of the University of North Carolina at Chapel Hill shared how PTN’s work is informing on the doses of medications commonly given to infants in the neonatal intensive care unit (NICU).

  • Representatives from the International Children’s Advisory Network (iCAN), a worldwide consortium of children’s advisory groups that provide a voice for children and families in medicine and research, shared their insights on pediatric clinical research and patient engagement.

  • Dr. Janice Sullivan of the University of Louisville School of Medicine discussed the successes and lessons learned from the IDeA States Pediatric Clinical Trials Network’s (ISPCTN) participation in the PTN POPS Study. 
LAPS Trial Enrolls More Than 100 Patients
The PTN Long-term Antipsychotic Pediatric Safety (LAPS) Trial, has enrolled more than 100 children, helping achieve nearly 30 percent of the overall enrollment goal of the study. Learn more about the trial and it's impact on children.
PTN Publishes Findings from Rifampin Study
A newly published PTN article in Antimicrobial Agents and Chemotherapy shares results from a study on rifampin, which is used to treat infections caused by methicillin-resistant staphylococcus and tuberculosis. The study, led by PTN investigator Dr. P. Brian Smith of the Duke University Department of Pediatrics, enrolled 27 infants and analyzed plasma pharmacokinetic samples and safety data to determine appropriate dosing of rifampin for infants. Learn more about the findings.

Introducing a New Process for Sharing Data and Samples

PTN now has a new process for requesting access to samples and/or data from its studies for additional testing. An investigator must access data and samples directly from the Data and Specimen Hub (DASH) . See the PTN Data Sharing page for more information.
STAR Program Trains Next Generation of Researchers
The Summer Training in Academic Research (STAR) Program welcomed 25 participants at its kickoff event in June. Now in its seventh year, the program provides hands-on research experience for undergraduate students, high school students, and middle and high school teachers during the summer academic break. Learn more about the program and its impact.
PTN hosted a booth at the recent International Children's Advisory Network (iCAN) Summit in Kansas City, Mo. Check out a few highlights from the Summit .

PTN and iCAN collaborate to strengthen pediatric research by incorporating patient and advocate voices. Learn more about iCAN .
Phyllis Kennel - PTN Program Manager - Left Leanne West - iCAN Steering Committee President - Right
Phyllis Kennel, PTN Program Manager (Left)
Leanne West, iCAN Steering Committee President (Right)
Recruiting soon:
  • Pharmacokinetics and Safety Profile of Digoxin in Infants with Single Ventricle Congenital Heart Disease
Currently enrolling:
  • Pharmacokinetics and Safety of Anesthetics and Analgesics in Children and Adolescents (ANA)
  • Long-term Antipsychotic Pediatric Safety Trial (LAPS)
  • Pharmacokinetics of Anti-epileptic Drugs in Obese Children (AED)
  • Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care (POPS)
  • Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants (CUDDLE)
  • Efficacy, Pharmacokinetics, and Safety of Topical Timolol in Infants with Infantile Hemangioma
  • Safety of Sildenafil in Premature Infants at Risk of Bronchopulmonary Dysplasia